NEWTOWN SQUARE, Penn., Nov. 15, 2016 /PRNewswire/ -- The world's premier nephrology meeting, the 50th annual American Society of Nephrology (ASN) Kidney Week 2016 conference is being held at Chicago, IL, Nov 15 – 20 https://www.asn-online.org/kidneyweek/. Kibow Biotech, Inc. is pleased to mark its 11th year of continued participation as an exhibitor and thus increasing awareness and understanding of its "Enteric Dialysis®" Technology. This technology was based on the original concept - "Will the Bowel be the Kidney of Future?" which is now called the Gut-Kidney connection. The Cleveland Clinic recently announced its list of Top 10 Medical innovations. Using the Microbiome to prevent, diagnose and treat disease is now recognized as the #1 MEDICAL INNOVATION with potential to transform healthcare (http://www.modernhealthcare.com/article/20161027/NEWS/161029924).
The company's patented technology is based on modulating the Gut Microbiome with specific strains of Probiotics and selected Prebiotics and thus helps maintain a healthy kidney function. The company has also been selected to present its scientific poster abstract on the use of Renadyl™ and its positive customer survey outcome at this conference. The abstract summarized the impact of Gut Microbiome on Quality of Life in customers with CKD using Renadyl™. Although it is a dietary supplement product, the company has performed extensive R&D, scientific and observational human clinical trials similar to any pharmaceutical product development.
Renadyl™, a probiotic and prebiotic dietary supplement, is currently sold online via Kibow websites, (www.renadyl.com or www.kibow.com). This probiotic supplement is known for its ability to target and help reduce the buildup of uremic toxins in the body, thus helping to maintain healthy kidney function, by means of Kibow's Uremic Toxin Reduction Technology. The probiotic microbial strains used in the product formulation are "Generally Recognized as Safe" (GRAS status), according to the regulations of U.S. FDA.
The company is currently exploring the various options of potentially advancing the product to prescription dietary supplement status that could qualify for medical reimbursement (e.g.; prenatal vitamins, enteral nutrition products etc.). Essentially, this will mandate obtaining an exemption of Investigator New Drug (IND) from the office of Dietary Supplement /US FDA. Subsequently, the company needs to accomplish additional human CKD Randomized Controlled Trials (RCT) in the forthcoming years in the US and several other countries. As a prescription dietary supplement, the product will gain greater acceptance by healthcare professionals and equally increased potential for marketing and sales towards Chronic Kidney Disease applications worldwide.
About Kibow Biotech: Established in 1997, Kibow Biotech specializes in research and development of probiotic/prebiotic dietary supplements. The Company's primary mission is to offer affordable, readily available and easily administered dietary supplements in support of kidney health. The Company's flagship product, Renadyl™, is currently marketed in the US and Canada, and will progressively be made available worldwide, according to the governmental rules and regulatory authorities of individual countries.
About Uremic Toxin Reduction Technology – Also known as "Enteric Dialysis®": Kibow's novel "uremic toxin removal technology" addresses the diffusion of various uremic toxins into the bowel as a consequence of failing kidney function. The Company's patented and proprietary dietary supplements, Renadyl™ (for humans) and Azodyl® for cats and dogs with moderate to severe kidney failure (a veterinary formulation licensed to Vetoquinol http://www.vetoquinolusa.com/) consists of a combination of three specific probiotic microbial strains and chosen prebiotics.
Forward-looking statements: This press release contains forward-looking statements that reflect management's current views of future events, including the status of development of the dietary supplement formulation, Renadyl™, for kidney health in the USA and the possibility of its approval as a drug in some other countries according to respective governmental authorities. Kibow is not a pharmaceutical company. Kibow products are not drugs and may not be considered as a treatment or a therapy. The dietary supplement formulation of Renadyl™ will not cure, prevent or mitigate any disease. Actual results may differ significantly from the above forward-looking statements due to a number of factors including but not limited to the possibility that Renadyl™ may not prove to be safe or show evidence of clinical activity in each and every individuals due to various environmental or genetic factors. Other factors that could cause or contribute to differences in actual results include, but are not limited to, whether or not the Company or any of its collaborators will be able to develop drug pathway using the technologies of the Company, whether the cash resources of the Company will be sufficient to fund operations as planned; reliance on key employees, especially senior management; the uncertainty of the Company's future access to capital; the risk that the Company may not secure or maintain relationships with collaborators, and the Company's dependence on intellectual property. The Company expressly disclaims any intent or obligation to update these forward-looking statements except as required by law.
Investor & Media Contact:
(610) 353 5130)
Read more news from Kibow Biotech Inc.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/kibow-biotech-further-validates-renadyl-towards-failing-kidney-function-and-its-original-concept-will-the-bowel-be-the-kidney-of-future-with-greater-understanding-and-recognition-in-the-1-emerging-field-of-microbiome-300363006.html
SOURCE Kibow Biotech, Inc.